Compare Travere Therapeutics Inc. Common Stock (TVTX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.86 (market cap $17.70B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 3.6× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and iShares Broad USD Investment Grade Corporate Bond for 46 Days on average.
| TVTX | USIG | |
|---|---|---|
Market Cap | $4.88B | $17.70B |
Volume | 1,668,577 | 2,181,370 |
Sector | Health | Fixed Income |
52-Week High | $67.52 | $52.69 |
52-Week Low | $26.79 | $48.54 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
USIG trades at $48.84 with minimal daily movement (+0.03%). Technical indicators show a bearish bias with moving averages signaling selling pressure, though oscillators remain neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The ETF maintains regular dividend distributions, with recent payments of $0.20-0.21 per share.
The investment grade corporate bond ETF faces headwinds from rising interest rate concerns, though institutional accumulation suggests confidence in its credit quality. Key risks include bond market volatility and credit spread fluctuations. Current technical weakness warrants caution despite the neutral sentiment from oscillators and institutional buying interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
